Home Cart Sign in  
Chemical Structure| 23094-69-1 Chemical Structure| 23094-69-1

Structure of Corilagin
CAS No.: 23094-69-1

Chemical Structure| 23094-69-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Corilagin can inhibit the interaction of DNA repair protein RAD52 and ssDNA with IC50 of 1.5 uM.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Corilagin

CAS No. :23094-69-1
Formula : C27H22O18
M.W : 634.45
SMILES Code : OC(C(O)=C(O)C=C1C(O[C@H]2[C@@H]([C@H](OC(C3=CC(O)=C(O)C(O)=C3)=O)O4)O)=O)=C1C(C(C(OC[C@@H]4[C@@H]2O)=O)=CC(O)=C5O)=C5O
MDL No. :MFCD00238565

Safety of Corilagin

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Corilagin

DNA

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Nrf2−/− HepG2 cells 30 μM 6 h Corilagin-mediated expression of antioxidant enzymes was blocked in Nrf2−/− HepG2 cells. Cell Commun Signal. 2019 Jan 10;17(1):2
HepG2 cells 7.5, 15, 30 μM 6 h Corilagin efficiently decreased APAP-triggered ROS generation and cell death, and induced the expression of several antioxidant enzymes. Cell Commun Signal. 2019 Jan 10;17(1):2
HEK293 0-100 μM 72 h Evaluate the effect of Corilagin on cell viability, results showed no cytotoxicity at 100 μM. Phytomedicine. 2021 Jul;87:153591
LO2 0-100 μM 72 h Evaluate the effect of Corilagin on cell viability, results showed no cytotoxicity at 100 μM. Phytomedicine. 2021 Jul;87:153591
Beas-2B 0-100 μM 72 h Evaluate the effect of Corilagin on cell viability, results showed no cytotoxicity at 100 μM. Phytomedicine. 2021 Jul;87:153591
GES-1 cells 0-100 µM 24 h To evaluate the toxicity of Corilagin on normal cells, results showed that Corilagin had low toxicity on GES-1 cells Int J Mol Med. 2019 Feb;43(2):967-979
BGC823 cells 0, 10, 20, 30, 40, 50 µM 24 h To evaluate the inhibitory effect of Corilagin on cell proliferation, results showed that Corilagin significantly inhibited the proliferation of BGC823 cells in a concentration-dependent manner Int J Mol Med. 2019 Feb;43(2):967-979
SGC7901 cells 0, 10, 20, 30, 40, 50 µM 24 h To evaluate the inhibitory effect of Corilagin on cell proliferation, results showed that Corilagin significantly inhibited the proliferation of SGC7901 cells in a concentration-dependent manner Int J Mol Med. 2019 Feb;43(2):967-979
Mouse peritoneal macrophages (MPMs) 100 µg/ml, 50 µg/ml, 25 µg/ml 24 h To study the effect of corilagin on the TLR4 signaling pathway in MPMs. Results showed that corilagin significantly inhibited the expression of TLR4 and its downstream molecules. Front Immunol. 2020 Aug 6;11:1611
Ana-1 cells 100 µg/ml, 50 µg/ml, 25 µg/ml 24 h To evaluate the cytotoxicity of corilagin on Ana-1 cells and its effect on the TLR4 signaling pathway. Results showed that corilagin significantly reduced the mRNA and protein expression of TLR4 and its downstream molecules. Front Immunol. 2020 Aug 6;11:1611
Mouse macrophage RAW 264.7 2 mg/ml 4 days Corilagin promotes macrophage transformation from pro-inflammatory M1 phenotype to anti-inflammatory M2 phenotype and upregulates the secretion of anti-inflammatory factors IL-10 and TGF-β. Regen Biomater. 2024 Jul 1;11:rbae074
Human umbilical vein endothelial cells (HUVECs) 2 mg/ml 4 days Corilagin modification not only enhances ECs adhesion and monolayer function via accelerating VEGF and TGF-β secretion but also promotes macrophage transformation from pro-inflammatory M1 phenotype to anti-inflammatory M2 ones. Regen Biomater. 2024 Jul 1;11:rbae074
HEK293T cells 3.33 μM (EC50) 24 h To evaluate the inhibitory effect of Corilagin on SARS-CoV-2 RdRp activity, results showed that Corilagin effectively inhibited RdRp activity. Acta Pharm Sin B. 2021 Jun;11(6):1555-1567
Huh-7 cells 4.96 μM (EC50) 48 h To evaluate the inhibitory effect of Corilagin on HCoV-OC43 replication, results showed that Corilagin effectively inhibited viral replication. Acta Pharm Sin B. 2021 Jun;11(6):1555-1567
Vero cells 0.13 μM (EC50) 48 h To evaluate the inhibitory effect of Corilagin on SARS-CoV-2 replication, results showed that Corilagin effectively inhibited viral replication. Acta Pharm Sin B. 2021 Jun;11(6):1555-1567

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6 mice APAP-induced acute liver failure model Intraperitoneally 15, 30, 60 mg/kg Twice (at 12-hour intervals) Corilagin significantly reduced APAP-induced mortality, ALT and AST levels, and attenuated liver histopathological changes. Cell Commun Signal. 2019 Jan 10;17(1):2
ApoE−/− mice High-fat and high-cholesterol diet-induced atherosclerosis model Intragastric administration 40, 20, 10 mg/kg Every 2 days for 2 weeks Corilagin effectively reduced serum lipid levels (TG, TC, and LDL-C), alleviated aortic pathological changes and intimal lipid deposition, and decreased the expression of molecules associated with the Olfr2 signaling pathway (Olfr2 and Adcy3) and NLRP3 inflammasome effectors (NLRP3, Caspase-1, NEK7, and ASC), as well as inflammatory cytokines (IL-1β, IL-18, and TNF-α). Front Immunol. 2024 May 13;15:1364161
C57BL/6J mice Con A-induced hepatitis model Intraperitoneal injection 25 mg/kg Twice, 12 hours apart To investigate the protective effect of Corilagin on Con A-induced liver injury. Results showed that Corilagin significantly increased the survival rate of mice, reduced serum ALT and AST levels, improved liver histopathological damage, reduced hepatocyte apoptosis and oxidative stress, and inhibited M1 macrophage activation. Front Immunol. 2022 Jan 13;12:807509
Sprague-Dawley rats Peripheral artery disease (PAD) model Intragastric administration 40 mg/kg·day, 20 mg/kg·day, 10 mg/kg·day Once daily for 1 month To evaluate the effect of corilagin on atherosclerotic plaques in PAD model rats. Results showed that corilagin significantly reduced plaque coverage area and inhibited the TLR4 signaling pathway and its downstream molecules. Front Immunol. 2020 Aug 6;11:1611

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.58mL

0.32mL

0.16mL

7.88mL

1.58mL

0.79mL

15.76mL

3.15mL

1.58mL

References

 

Historical Records

Categories